| Immunotherapy in cancer: a combat between tumors and the immune system; you win some, you lose some FP Madorsky Rowdo, A Baron, M Urrutia, J Mordoh Frontiers in Immunology 6, 127, 2015 | 65 | 2015 |
| Extracellular matrix in synthetic hydrogel‐based prostate cancer organoids regulate therapeutic response to EZH2 and DRD2 inhibitors MJ Mosquera, S Kim, R Bareja, Z Fang, S Cai, H Pan, M Asad, ML Martin, ... Advanced Materials 34 (2), 2100096, 2022 | 41 | 2022 |
| Gut microbiota-derived metabolites confer protection against SARS-CoV-2 infection JA Brown, KZ Sanidad, S Lucotti, CM Lieber, RM Cox, ... Gut Microbes 14 (1), 2105609, 2022 | 38 | 2022 |
| Gut bacteria–derived serotonin promotes immune tolerance in early life KZ Sanidad, SL Rager, HC Carrow, A Ananthanarayanan, R Callaghan, ... Science Immunology 9 (93), eadj4775, 2024 | 27 | 2024 |
| Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long‑term BRAF inhibition FP Madorsky Rowdo, A Baron, SJ Gallagher, P Hersey, AA Emran, ... International journal of oncology 56 (6), 1429-1441, 2020 | 27 | 2020 |
| In vitro long-term treatment with MAPK inhibitors induces melanoma cells with resistance plasticity to inhibitors while retaining sensitivity to CD8 T cells FPM Rowdo, A Baron, EM Von Euw, J Mordoh Oncology Reports 37 (3), 1367-1378, 2017 | 9 | 2017 |
| Melanoma vaccines and modulation of the immune system in the clinical setting: building from new realities FP Madorsky-Rowdo, ML Lacreu, J Mordoh Frontiers in immunology 3, 103, 2012 | 9 | 2012 |
| Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment FPM Rowdo, G Xiao, GF Khramtsova, J Nguyen, R Martini, B Stonaker, ... Cancer Letters 584, 216608, 2024 | 6 | 2024 |
| High lipid content of irradiated human melanoma cells does not affect cytokine-matured dendritic cell function GA Pizzurro, FP Madorsky Rowdo, LM Pujol-Lereis, LA Quesada-Allué, ... Cancer Immunology, Immunotherapy 62, 3-15, 2013 | 6 | 2013 |
| The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution DD Nguyen, WF Hooper, W Liu, TR Chu, H Geiger, JM Shelton, M Shah, ... Nature, 1-10, 2024 | 1 | 2024 |
| Kinome focused CRISPR-Cas9 screens in African ancestry patient-derived breast cancer organoids identifies essential kinases and synergy of EGFR and FGFR1 inhibition FPM Rowdo, R Martini, S Ackermann, C Tang, M Tranquille, A Irizarry, ... bioRxiv, 2023.12. 11.570465, 2023 | 1 | 2023 |
| Immunization of cutaneous melanoma patients with the allogeneic cell vaccine CSF-470 enhances immune infiltration of metastatic lesions and would favor subsequent response to … M Aris, MB Pampena, EM Levy, AI Bravo, FP Madorsky-Rowdo, A Mordoh, ... CANCER IMMUNOLOGY RESEARCH 3 (10), 2015 | 1 | 2015 |
| Kinome focused CRISPR-Cas9 screens in African ancestry patient-derived breast cancer organoids identify essential kinases and synergy of EGFR and FGFR1 inhibition ML Martin, R Martini, S Ackermann, C Tang, M Tranquille, A Irizarry, I Us, ... | | 2024 |
| Patient-derived tumor organoids with p53 mutations, and not wild-type p53, demonstrate synergistic sensitivity to treatment with temozolomide in combination with talazoparib … FPM Rowdo, G Xiao, MB Davis, L Martin, O Elemento, J Bargonetti Cancer Research 83 (7_Supplement), 6186-6186, 2023 | | 2023 |
| Up284, A small molecule inhibitor of ADRM1 demonstrates significant anti-tumor efficacy in preclinical models of aggressive breast cancer B Karanam, R Anchoori, YN Chang, R Martini, FM Rowdo, MB Davis Cancer Research 83 (7_Supplement), 4478-4478, 2023 | | 2023 |
| 344 The Potential Benefits of Using Senolytics in Colorectal Cancer Treatment V Gallegos, FM Rowdo, J White, HH Kuo, E Podaza, L Martin, O Elemento Journal of Clinical and Translational Science 7 (s1), 102-102, 2023 | | 2023 |
| Patient-Derived Organoids model time-dependent sensitivities to PARP inhibitors in patients with metastatic colorectal cancer. M Mastropaolo, H Kuo, J Nguyen, FM Rowdo, J Capuano, J Moyer, ... CANCER IMMUNOLOGY RESEARCH 10 (12), 2022 | | 2022 |
| Abstract B55: Patient-Derived Organoids model time-dependent sensitivities to PARP inhibitors in patients with metastatic colorectal cancer M Mastropaolo, H Kuo, J Nguyen, FM Rowdo, J Capuano, J Moyer, ... Cancer Immunology Research 10 (12_Supplement), B55-B55, 2022 | | 2022 |
| Kinome crispr cas9 screening in breast cancer organoids derived from Ghanaian patients FPM Rowdo, S Ackermann, JK Oppong, I Kyei, C Tang, L Newman, ... Cancer Research 82 (12_Supplement), 6037-6037, 2022 | | 2022 |
| Extracellular Matrix in Synthetic Hydrogel‐Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors (Adv. Mater. 2/2022) MJ Mosquera, S Kim, R Bareja, Z Fang, S Cai, H Pan, M Asad, ML Martin, ... Advanced Materials 34 (2), 2270014, 2022 | | 2022 |
